EA201101531A1 - Способ лечения острого миелоидного лейкоза - Google Patents

Способ лечения острого миелоидного лейкоза

Info

Publication number
EA201101531A1
EA201101531A1 EA201101531A EA201101531A EA201101531A1 EA 201101531 A1 EA201101531 A1 EA 201101531A1 EA 201101531 A EA201101531 A EA 201101531A EA 201101531 A EA201101531 A EA 201101531A EA 201101531 A1 EA201101531 A1 EA 201101531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
myeloid leukemia
acute myeloid
mirna
treating acute
methods
Prior art date
Application number
EA201101531A
Other languages
English (en)
Inventor
Боб Лёвенберг
Мойка Лавренсик
Петер Якобус Мария Валк
Су Мин Сун
Original Assignee
Эразмус Юниверсити Медикал Сентер Роттердам
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эразмус Юниверсити Медикал Сентер Роттердам filed Critical Эразмус Юниверсити Медикал Сентер Роттердам
Publication of EA201101531A1 publication Critical patent/EA201101531A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к области молекулярной медицины и обеспечивает способы лечения острого миелоидного лейкоза. Данные способы основаны на наблюдении того, что микроРНК-9 и/или микроРНК-9* (микроРНК-9/9*) вовлечены в патогенез заболевания, так как сверхэкспрессия микроРНК9/9* блокирует миелоидную дифференцировку in vitro. Более конкретно, было обнаружено, что микроРНК-9/9* играют некоторую роль в лейкозной трансформации при остром миелоидном лейкозе.
EA201101531A 2009-04-22 2010-04-22 Способ лечения острого миелоидного лейкоза EA201101531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09158496A EP2243833A1 (en) 2009-04-22 2009-04-22 Method for the treatment of acute myeloid leukemia
PCT/EP2010/055355 WO2010122109A1 (en) 2009-04-22 2010-04-22 Method for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
EA201101531A1 true EA201101531A1 (ru) 2012-05-30

Family

ID=40935648

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101531A EA201101531A1 (ru) 2009-04-22 2010-04-22 Способ лечения острого миелоидного лейкоза

Country Status (10)

Country Link
US (1) US20120088811A1 (ru)
EP (2) EP2243833A1 (ru)
JP (1) JP2012524758A (ru)
KR (1) KR20110138414A (ru)
CN (1) CN102421899A (ru)
BR (1) BRPI1016182A2 (ru)
CA (1) CA2759597A1 (ru)
EA (1) EA201101531A1 (ru)
MX (1) MX2011010610A (ru)
WO (1) WO2010122109A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2697374A2 (en) 2011-04-12 2014-02-19 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
JP6156621B2 (ja) * 2012-02-14 2017-07-05 国立大学法人 岡山大学 Ａｔｌｌの診断のためのデータ取得方法、ａｔｌｌ診断用キットおよびａｔｌｌ診断システム
WO2015026827A2 (en) * 2013-08-19 2015-02-26 University Of Notre Dame Method and composition for detection of oncogenic hpv
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
KR101476781B1 (ko) * 2014-05-09 2014-12-29 충남대학교산학협력단 결핵 진단용 바이오마커 마이크로 rna
WO2017009843A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
CN106367474B (zh) * 2015-07-21 2020-01-31 益善生物技术股份有限公司 18种miRNA检测探针和液相芯片
CA3014530A1 (en) * 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
CN114392346A (zh) * 2022-01-19 2022-04-26 山东大学齐鲁医院 亨廷顿相互作用蛋白-1相关蛋白基因和/或其编码的蛋白的新应用

Also Published As

Publication number Publication date
US20120088811A1 (en) 2012-04-12
MX2011010610A (es) 2012-01-30
WO2010122109A9 (en) 2011-02-17
BRPI1016182A2 (pt) 2019-09-24
EP2421968A1 (en) 2012-02-29
EP2243833A1 (en) 2010-10-27
KR20110138414A (ko) 2011-12-27
CA2759597A1 (en) 2010-10-28
CN102421899A (zh) 2012-04-18
WO2010122109A1 (en) 2010-10-28
JP2012524758A (ja) 2012-10-18

Similar Documents

Publication Publication Date Title
EA201101531A1 (ru) Способ лечения острого миелоидного лейкоза
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1119964T1 (el) Αναστολεις οδου σηματοδοτησης notch και χρηση αυτων στη θεραπευτικη αγωγη καρκινων
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA200900064A1 (ru) Ингибирование агрегации альфа-синуклеина
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201070595A1 (ru) Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
MX2016012716A (es) Compuestos y metodos para suministro trans-membrana de moleculas.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CL2011001313A1 (es) Compuestos derivados de n-(fenil)-sulfonilamina, inhibidores de bcl2 o bcl-xl; composicion farmaceutica; y su uso en el tratamiento de cancer de vejiga, cerebro, mamas, medula osea, cervical, colorrectal, esofago, cancer hepatocelular, leucemia linfoblastica, linfoma folicular, mieloma.
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
TW200740844A (en) Novel MAdCAM antibodies
NZ607996A (en) Substituted nucleotide analogs
EA201171367A1 (ru) Винилиндазолильные соединения
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств